The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | The impact of lenalidomide on second primary malignancies: long-term data from the Myeloma XI Trial
Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone, New York City, NY, shares the results of a study evaluating the impact of lenalidomide on second primary malignancies (SPM) development when used at induction and maintenance therapy for patients with multiple myeloma. Overall, the data demonstrated that there was very little risk of SPM development with lenalidomide, with only a few incidences of skin cancer recorded. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
